A study to evaluate the effectiveness of a new chemotherapy regimen for breast cancer comparing to the standard chemotherapy.
Phase 2
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2023/05/052756
- Lead Sponsor
- CMC Vellore
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Documented histologically confirmed invasive ductal carcinoma of the breast
ECOG Performance Status 0-2
Hormone Receptor Status should be documented as negative
HER2 documented negative
Stage I-IIIC
Exclusion Criteria
Pregnant, breastfeeding
Multicentric or bilateral disease
neuropathy grade 2 or above
CCF NYHA class 3 or above
LV dysfunction
creatinine clearance less than 60 ml
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method